Sitagliptin Phosphate Monohydrate Treated for Type 2 diabetes CAS Number 654671-77-9

Basic Info

Model No.: 654671-77-9

Additional Info

Packaging: 25KGS/DRUM

Productivity: 40T/Y

Brand: VOLSENCHEM

Transportation: Ocean,Land,Air

Place of Origin: CHINA

Product Description

Sitagliptin phosphate monohydrate CAS number 654671-77-9, a new drug for the treatment of type 2 diabetes. In August 2009, the drug was approved by the European Union as a first-line drug for the treatment of type 2 diabetes. After 2011, one after another countries have approved the combination of sitagliptin phosphate and alpha glycosidase inhibitors or insulin. Sitagliptin phosphate is the first FDA-approved dipeptidyl peptidase-IV inhibitor to be used in the treatment of type 2 diabetes by far, under the trade name Januvia. Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) rapidly and effectively degrades GLP-1, GLP-1, which is the most effective stimulator of insulin production and secretion Therefore, inhibition of DPP-IV can enhance the role of endogenous GLP-1, thereby increasing blood insulin levels, thereby reducing and maintaining blood glucose levels in diabetic patients. At present, medicine has confirmed that DPP-IV inhibitor is a new type of anti-diabetic drug, and clinical results show that the drugs have a good hypoglycemic effect. Because GLP-1 plays a glucose-dependent role in promoting insulin production and secretion, common adverse reactions such as hypoglycemia and weight gain caused by the use of antidiabetic drugs do not occur.
The mechanism of action of sitagliptin phosphate monohydrate CAS 654671-77-9 is differs from the previous oral hypoglycemic agents in that it increases insulin secretion by increasing the insulin production of pancreatic islet β cells in diabetic patients. When the blood sugar is elevated (eg, after eating), the body's gastrointestinal endocrine cells secrete two incretin hormones, glucagon-like peptide-1 (GLP-1) and intestinal inhibitory peptide (GIP) Cells secrete insulin to control blood sugar levels. sitagliptin phosphate monohydrate CAS 654671-77-9 has been shown to be a safe, effective and well-established oral medication for type 2 diabetes.

Thera. Category: Anti-Diabetes

Cas No.:654671-77-9

Synonym:Sitagliptin phosphate mon;Sitagliptin phosphate monohydrate, >=99%;7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate (1:1) monohydrate;(R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4;Sitagliptin phosphate monohydrate;Sitagliptin phosphate for research;7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)Butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazinephosphatemonohydrate;Sitagliptin phosphate monohydrate 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate monohydrate;

Molecular Structure:  

Molecular Formula:C16H20F6N5O6P

Molecular Weight: 523.3240802

Pharmacopeia: In house Spec.

Specifications:Available on request

Packing:Export worthy packing

Material Safety Data Sheet:Available on request